Aptose Biosciences (TSE:APS) Sets New 52-Week High – Here’s What Happened

Aptose Biosciences Inc. (TSE:APS) (NASDAQ:APTO) shares hit a new 52-week high during trading on Thursday . The company traded as high as C$2.40 and last traded at C$2.40, with a volume of 28032 shares trading hands. The stock had previously closed at C$2.14.

Aptose Biosciences Trading Up 12.1%

The business has a 50 day simple moving average of C$2.26 and a two-hundred day simple moving average of C$2.23. The company has a current ratio of 0.55, a quick ratio of 5.41 and a debt-to-equity ratio of -98.74. The stock has a market cap of C$6.12 million, a price-to-earnings ratio of -0.23 and a beta of -1.38.

Aptose Biosciences (TSE:APS) (NASDAQ:APTO) last announced its earnings results on Wednesday, May 13th. The biotechnology company reported C($4.16) earnings per share (EPS) for the quarter. As a group, equities analysts anticipate that Aptose Biosciences Inc. will post -0.59 EPS for the current year.

Aptose Biosciences Company Profile

Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies. The company has an agreement with CrystalGenomics, Inc to research, develop, and commercialize CG026806, a non-covalent small molecule therapeutic agent, which is in preclinical stage for the treatment of acute myeloid leukemia and chronic lymphocytic leukemia/mantle cell lymphoma.